Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment. (I). Nonalcoholic fatty liver disease and its association with cardiovascular disease;Enfermedad del hígado graso no alcohólico, asociación con la enfermedad cardiovascular y tratamiento (I). Enfermedad del hígado graso no alcohólico y su asociación con la enfermedad cardiovascular

Clinica e Investigacion en Arteriosclerosis

Volumn 29, Issue 3, 2017, Pages 141-148

  Brea, Ángel ^a   Pintó, Xavier ^b   Ascaso, Juan F ^c   Blasco, Mariano ^d   Díaz, Ángel ^e   González Santos, Pedro ^f   Hernández Mijares, Antonio ^g   Mantilla, Teresa ^h   Millán, Jesús ⁱ   Pedro Botet, Juan ^j  

^a HOSPITAL SAN PEDRO   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^d Centro de Salud Almozara   (Spain)

^e Medicina Familiar y Comunitaria Centro de Salud de Bembibre   (Spain)

^f UNIVERSITY OF MÁLAGA   (Spain)

^g HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^h Centro de Salud de Torrelodones   (Spain)

ⁱ HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^j UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

more..

Author keywords

Atherosclerosis; Cardiovascular diseases; Cardiovascular risk; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Treatment

Indexed keywords

ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; LIVER CANCER; LIVER CIRRHOSIS; MORBIDITY; MORTALITY; NONALCOHOLIC FATTY LIVER; PREVALENCE; RISK FACTOR; SHORT SURVEY; ATHEROSCLEROSIS; COMPLICATION; DISEASE EXACERBATION; HUMAN; PATHOPHYSIOLOGY;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; HUMANS; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTORS;

EID: 84998890594     PISSN: 02149168     EISSN: 15781879     Source Type: Journal    
DOI: 10.1016/j.arteri.2016.06.003     Document Type: Short Survey

References (86)

1. 1 Neuschwander-Tetri, B.A., Caldwell, S.H., Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 37 (2003), 1202–1219.
2. 2 Musso, G., Gambino, R., Cassader, M., Pagano, G., Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive test for liver disease severity. Ann Med 43 (2011), 617–649.
3. 3 Sanyal, A.J., Banas, C., Sargeant, C., Luketic, V.A., Sterling, R.K., Stravitz, R.T., et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 43 (2006), 682–689.
4. 4 Bugianesi, E., Leone, N., Vanni, E., Marchesini, G., Brunello, F., Carucci, P., et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 123 (2002), 134–140.
5. 5 Blachier, M., Leleu, H., Peck-Radosavljevic, M., Valla, D.C., Roudot-Thoraval, F., The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 58 (2013), 593–608.
6. 6 Ampuero, J., Gallego-Durán, R., Romero-Gómez, M., Association of NAFLD with subclinical atherosclerosis and coronary-artery disease: Meta-analysis. Rev Esp Enferm Dig 107 (2015), 10–16.
7. 7 Caballería, L., Pera, G., Auladell, M.A., Torán, P., Muñoz, L., Miranda, D., et al. Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain. Eur J Gastroenterol Hepatol 22 (2010), 24–32.
8. 8 Brea, A., Mosquera, D., Martín, E., Arizti, A., Cordero, J.L., Ros, E., Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler Thromb Vasc Biol 25 (2005), 1045–1050.
9. 9 Volzke, H., Robinson, D.M., Kleine, V., Deutscher, R., Hoffmann, W., Ludemann, J., et al. Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. World J Gastroenterol 11 (2005), 1848–1853.
10. 10 Targher, G., Bertolini, L., Padovani, R., Rodella, S., Zoppini, G., Zenari, L., et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 29 (2006), 1325–1330.
11. 11 Targher, G., Bertolini, L., Padovani, R., Zenari, L., Zoppini, G., Falezza, G., Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation. Diabetes Care 27 (2004), 2498–2500.
12. 12 Fracanzani, A.L., Burdick, L., Raselli, S., Pedotti, P., Grigore, L., Santorelli, G., et al. Carotid artery intima-media thickness in nonalcoholic fatty liver disease. Am J Med 121 (2008), 72–78.
13. 13 Sookoian, S., Pirola, C.J., Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol 49 (2008), 600–607.
14. 14 Chen, Y., Xu, M., Wang, T., Sun, J., Sun, W., Xu, B., et al. Advanced fibrosis associates with atherosclerosis in subjects with nonalcoholic fatty liver disease. Atherosclerosis 241 (2015), 145–150.
15. 15 Fracanzani, A.L., Tiraboschi, S., Pisano, G., Consonni, D., Baragetti, A., Bertelli, C., et al. Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10 years of follow-up. Atherosclerosis 246 (2016), 208–213.
16. 16 Bhatia, L., Scorletti, E., Curzen, N., Clough, G.F., Calder, P.C., Byrne, C.D., Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression. Atherosclerosis 246 (2015), 13–20.
17. 17 Arslan, U., Türkoğlu, S., Balcioğlu, S., Tavil, Y., Karakan, T., Cengel, A., Association between nonalcoholic fatty liver disease and coronary artery disease. Coron Artery Dis 18 (2007), 433–436.
18. 18 Assy, N., Djibre, A., Farah, R., Grosovski, M., Marmor, A., Presence of coronary plaques in patients with nonalcoholic fatty liver disease. Radiology 254 (2010), 393–400.
19. 19 Chen, C.H., Nien, C.K., Yang, C.C., Yeh, Y.H., Association between nonalcoholic fatty liver disease and coronary artery calcification. Dig Dis Sci 55 (2010), 1752–1760.
20. 20 Chhabra, R., O'Keefe, J.H., Patil, H., O'Keefe, E., Thompson, R.C., Ansari, S., et al. Association of coronary artery calcification with hepatic steatosis in asymptomatic individuals. Mayo Clin Proc 88 (2013), 1259–1265.
21. 21 Akabame, S., Hamaguchi, M., Tomiyasu, K., Tanaka, M., Kobayashi-Takenaka, Y., Nakano, K., et al. Evaluation of vulnerable coronary plaques and non-alcoholic fatty liver disease (NAFLD) by 64-detector multislice computed tomography (MSCT). Circ J 72 (2008), 618–625.
22. 22 Osawa, K., Miyoshi, T., Yamauchi, K., Koyama, Y., Nakamura, K., Sato, S., et al. Nonalcoholic hepatic steatosis is a strong predictor of high-risk coronary-artery plaques as determined by multidetector CT. PLoS One, 10, 2015, e0131138.
23. 23 Puchner, S.B., Lu, M.T., Mayrhofer, T., Liu, T., Pursnani, A., Ghoshhajra, B.B., et al. High-risk coronary plaque at coronary CT angiography is associated with nonalcoholic fatty liver disease, independent of coronary plaque and stenosis burden: results from the ROMICAT II trial. Radiology 274 (2015), 693–701.
24. 24 Villanova, N., Moscatiello, S., Ramilli, S., Bugianesi, E., Magalotti, D., Vanni, E., et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 42 (2005), 473–480.
25. 25 Musso, G., Gambino, R., Bo, S., Uberti, B., Biroli, G., Pagano, G., et al. Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects. Diabetes Care 31 (2008), 562–568.
26. 26 Salvi, P., Ruffini, R., Agnoletti, D., Magnani, E., Pagliarani, G., Comandini, G., et al. Increased arterial stiffness in nonalcoholic fatty liver disease: the Cardio-GOOSE study. J Hypertens 28 (2010), 1699–1707.
27. 27 Vlachopoulos, C., Manesis, E., Baou, K., Papatheodoridis, G., Koskinas, J., Tiniakos, D., et al. Increased arterial stiffness and impaired endothelial function in nonalcoholic Fatty liver disease: a pilot study. Am J Hypertens 23 (2010), 1183–1189.
28. 28 Oni, E.T., Agatston, A.S., Blaha, M.J., Fialkow, J., Cury, R., Sposito, A., et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?. Atherosclerosis 230 (2013), 258–267.
29. 29 Goland, S., Shimoni, S., Zornitzki, T., Knobler, H., Azoulai, O., Lutaty, G., et al. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J Clin Gastroenterol 40 (2006), 949–955.
30. 30 Perseghin, G., Lattuada, G., De Cobelli, F., Esposito, A., Belloni, E., Ntali, G., et al. Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology 47 (2008), 51–58.
31. 31 Bonapace, S., Perseghin, G., Molon, G., Canali, G., Bertolini, L., Zoppini, G., et al. Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes. Diabetes Care 35 (2012), 389–395.
32. 32 Yilmaz, Y., Kurt, R., Yonal, O., Polat, N., Celikel, C.A., Gurdal, A., et al. Coronary flow reserve is impaired in patients with nonalcoholic fatty liver disease: association with liver fibrosis. Atherosclerosis 211 (2010), 182–186.
33. 33 Pohle, K., Otte, M., Mäffert, R., Ropers, D., Schmid, M., Daniel, W.G., et al. Association of cardiovascular risk factors to aortic valve calcification as quantified by electron beam computed tomography. Mayo Clin Proc 79 (2004), 1242–1246.
34. 34 Bonapace, S., Valbusa, F., Bertolini, L., Pichiri, I., Mantovani, A., Rossi, A., et al. Nonalcoholic fatty liver disease is associated with aortic valve sclerosis in patients with type 2 diabetes mellitus. PLoS One, 9, 2014, e88371.
35. 35 Mantovani, A., Pernigo, M., Bergamini, C., Bonapace, S., Lipari, P., Valbusa, F., et al. Heart valve calcification in patients with type 2 diabetes and nonalcoholic fatty liver disease. Metabolism 64 (2015), 879–887.
36. 36 Sinner, M.F., Wang, N., Fox, C.S., Fontes, J.D., Rienstra, M., Magnani, J.W., et al. Relation of circulating liver transaminase concentrations to risk of new-onset atrial fibrillation. Am J Cardiol 111 (2013), 219–224.
37. 37 Alonso, A., Misialek, J.R., Amiin, M.A., Hoogeveen, R.C., Chen, L.Y., Agarwal, S.K., et al. Circulating levels of liver enzymes and incidence of atrial fibrillation: the atherosclerosis risk in communities cohort. Heart 100 (2014), 1511–1516.
38. 38 Targher, G., Mantovani, A., Pichiri, I., Rigolon, R., Dauriz, M., Zoppini, G., et al. Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes. Clin Sci (Lond) 125 (2013), 301–309.
39. 39 Targher, G., Valbusa, F., Bonapace, S., Bertolini, L., Zenari, L., Rodella, S., et al. Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PLoS One, 8, 2013, e57183.
40. 40 Lin, Y.C., Lo, H.M., Chen, J.D., Sonographic fatty liver, overweight and ischemic heart disease. World J Gastroenterol 11 (2005), 4838–4842.
41. 41 Wong, V.W., Wong, G.L., Yip, G.W., Lo, A.O., Limquiaco, J., Chu, W.C., et al. Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut 60 (2011), 1721–1727.
42. 42 Targher, G., Bertolini, L., Padovani, R., Rodella, S., Tessari, R., Zenari, L., et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30 (2007), 1212–1218.
43. 43 Targher, G., Bertolini, L., Padovani, R., Poli, F., Scala, L., Tessari, R., et al. Increased prevalence of cardiovascular disease in Type 2 diabetic patients with non-alcoholic fatty liver disease. Diabet Med 23 (2006), 403–409.
44. 44 Lu, H., Zeng, L., Liang, B., Shu, X., Xie, D., High prevalence of coronary heart disease in type 2 diabetic patients with non-alcoholic fatty liver disease. Arch Med Res 40 (2009), 571–575.
45. 45 Targher, G., Pichiri, I., Zoppini, G., Trombetta, M., Bonora, E., Increased prevalence of cardiovascular disease in Type 1 diabetic patients with non-alcoholic fatty liver disease. J Endocrinol Invest 35 (2012), 535–540.
46. 46 Schwimmer, J.B.D.R., Behling, C., Lavine, J.E., Fatty liver as a determinant of atherosclerosis. Hepatology, 42, 2005, 610A [Abstract].
47. 47 Mellinger, J.L., Pencina, K.M., Massaro, J.M., Hoffmann, U., Seshadri, S., Fox, C.S., et al. Hepatic steatosis and cardiovascular disease outcomes: An analysis of the Framingham Heart Study. J Hepatol 63 (2015), 470–476.
48. 48 Wannamethee, G., Ebrahim, S., Shaper, A.G., Gamma-glutamyltransferase: determinants and association with mortality from ischemic heart disease and all causes. Am J Epidemiol 142 (1995), 699–708.
49. 49 Ruttmann, E., Brant, L.J., Concin, H., Diem, G., Rapp, K., Ulmer, H., et al. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation 112 (2005), 2130–2137.
50. 50 Lee, D.H., Silventoinen, K., Hu, G., Jacobs, D.R., Jousilahti, P., Sundvall, J., et al. Serum gamma-glutamyltransferase predicts non-fatal myocardial infarction and fatal coronary heart disease among 28,838 middle-aged men and women. Eur Heart J 27 (2006), 2170–2176.
51. 51 Schindhelm, R.K., Dekker, J.M., Nijpels, G., Bouter, L.M., Stehouwer, C.D., Heine, R.J., et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 191 (2007), 391–396.
52. 52 Lee, D.S., Evans, J.C., Robins, S.J., Wilson, P.W., Albano, I., Fox, C.S., et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 27 (2007), 127–133.
53. 53 Dunn, W., Xu, R., Wingard, D.L., Rogers, C., Angulo, P., Younossi, Z.M., et al. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol 103 (2008), 2263–2271.
54. 54 Ong, J.P., Pitts, A., Younossi, Z.M., Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 49 (2008), 608–612.
55. 55 Strasak, A.M., Kelleher, C.C., Klenk, J., Brant, L.J., Ruttmann, E., Rapp, K., et al. Longitudinal change in serum gamma-glutamyltransferase and cardiovascular disease mortality: a prospective population-based study in 76,113 Austrian adults. Arterioscler Thromb Vasc Biol 28 (2008), 1857–1865.
56. 56 Fraser, A., Harris, R., Sattar, N., Ebrahim, S., Smith, G.D., Lawlor, D.A., Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta-Analysis. Arterioscler Thromb Vasc Biol 27 (2007), 2729–2735.
57. 57 Wannamethee, S.G., Lennon, L., Shaper, A.G., The value of gamma-glutamyltransferase in cardiovascular risk prediction in men without diagnosed cardiovascular disease or diabetes. Atherosclerosis 201 (2008), 168–175.
58. 58 Williams, K.H., Sullivan, D.R., Veillard, A.S., O'Brien, R., George, J., Jenkins, A.J., et al. Low alanine aminotransferase levels and higher number of cardiovascular events in people with Type 2 diabetes: analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabet Med, 2015.
59. 59 Jepsen, P., Vilstrup, H., Mellemkjaer, L., Thulstrup, A.M., Olsen, J.H., Baron, J.A., et al. Prognosis of patients with a diagnosis of fatty liver–a registry-based cohort study. Hepatogastroenterology 50 (2003), 2101–2104.
60. 60 Targher, G., Bertolini, L., Poli, F., Rodella, S., Scala, L., Tessari, R., et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 54 (2005), 3541–3546.
61. 61 Targher, G., Bertolini, L., Rodella, S., Tessari, R., Zenari, L., Lippi, G., et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 30 (2007), 2119–2121.
62. 62 Hamaguchi, M., Kojima, T., Takeda, N., Nagata, C., Takeda, J., Sarui, H., et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 13 (2007), 1579–1584.
63. 63 Kleiner, D.E., Brunt, E.M., Van Natta, M., Behling, C., Contos, M.J., Cummings, O.W., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005), 1313–1321.
64. 64 Teli, M.R., James, O.F., Burt, A.D., Bennett, M.K., Day, C.P., The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 22 (1995), 1714–1719.
65. 65 Matteoni, C.A., Younossi, Z.M., Gramlich, T., Boparai, N., Liu, Y.C., McCullough, A.J., Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116 (1999), 1413–1419.
66. 66 Adams, L.A., Lymp, J.F., St Sauver, J., Sanderson, S.O., Lindor, K.D., Feldstein, A., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129 (2005), 113–121.
67. 67 Ekstedt, M., Franzén, L.E., Mathiesen, U.L., Thorelius, L., Holmqvist, M., Bodemar, G., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44 (2006), 865–873.
68. 68 Adams, L.A., Harmsen, S., St Sauver, J.L., Charatcharoenwitthaya, P., Enders, F.B., Therneau, T., et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol 105 (2010), 1567–1573.
69. 69 Dam-Larsen, S., Franzmann, M., Andersen, I.B., Christoffersen, P., Jensen, L.B., Sørensen, T.I., et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 53 (2004), 750–755.
70. 70 Lu, H., Liu, H., Hu, F., Zou, L., Luo, S., Sun, L., Independent association between nonalcoholic fatty liver disease and cardiovascular disease: a systematic review and meta-analysis. Int J Endocrinol, 2013, 2013, 124958.
71. 71 Takahashi, Y., Kurosaki, M., Tamaki, N., Yasui, Y., Hosokawa, T., Tsuchiya, K., et al. NAFLD fibrosis score and FIB-4 scoring system could identify patients at risk for systemic complications. Hepatol Res, 2014.
72. 72 Kim, D., Kim, W.R., Kim, H.J., Therneau, T.M., Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 57 (2013), 1357–1365.
73. 73 Byrne, C.D., Targher, G., NAFLD: a multisystem disease. J Hepatol 62:1 Suppl (2015), S47–S64.
74. 74 Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61 (2015), 1547–1554.
75. 75 Lazo, M., Hernaez, R., Bonekamp, S., Kamel, I.R., Brancati, F.L., Guallar, E., et al. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ, 343, 2011, d6891.
76. 76 Stepanova, M., Younossi, Z.M., Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol 10 (2012), 646–650.
77. 77 Treeprasertsuk, S., Leverage, S., Adams, L.A., Lindor, K.D., St Sauver, J., Angulo, P., The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int 32 (2012), 945–950.
78. 78 Armstrong, M.J., Adams, L.A., Canbay, A., Syn, W.K., Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology 59 (2014), 1174–1197.
79. 79 Rabar, S., Harker, M., O'Flynn, N., Wierzbicki, A.S., Group, G.D., Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance. BMJ, 349, 2014, g4356.
80. 80 Lonardo, A., Ballestri, S., Targher, G., Loria, P., Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 9 (2015), 629–650.
81. 81 Brea, A.M.D., Martin, E., Arizti, A., Palomo, M.J., Cardiovascular risk in nonalcoholic fatty liver disease. Atherosclerosis, 3(sup 2), 2002, 79 [Abstract].
82. 82 Ioannou, G.N., Weiss, N.S., Boyko, E.J., Mozaffarian, D., Lee, S.P., Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology 43 (2006), 1145–1151.
83. 83 Gastaldelli, A., Kozakova, M., Højlund, K., Flyvbjerg, A., Favuzzi, A., Mitrakou, A., et al. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 49 (2009), 1537–1544.
84. 84 Sung, K.C., Ryan, M.C., Wilson, A.M., The severity of nonalcoholic fatty liver disease is associated with increased cardiovascular risk in a large cohort of non-obese Asian subjects. Atherosclerosis 203 (2009), 581–586.
85. 85 Targher, G., Arcaro, G., Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 191 (2007), 235–240.
86. 86 Brea, A., Puzo, J., Non-alcoholic fatty liver disease and cardiovascular risk. Int J Cardiol 167 (2013), 1109–1117.